Disconnectome mapping provides a comprehensive understanding of how structural damage translates to cognitive dysfunction. Lesion-based disconnectome mapping suggests that the pattern, not the ...

Shares of uniQure N.V. QURE skyrocketed 247.7% on Wednesday after the company reported meeting key goals in the pivotal early to mid-stage study of its investigational gene therapy, AMT-130, for the ...

The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat Huntington’s disease. Globally, an estimated 4.88 per 100,000 people ...

uniQure N.V. (NASDAQ:QURE) on Wednesday released topline data from the pivotal Phase 1/2 study of AMT-130 for Huntington’s disease. Huntington’s disease is an inherited condition in which nerve cells ...

Sage Therapeutics' run of bad news has continued with a failed phase 2 trial of dalzanemdor as a treatment for cognitive impairment associated with Huntington's disease, spelling the end of the ...

~ Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by cUHDRS compared to a propensity score-matched external ...

Long-chain omega-3 fatty acids could have neuroprotective properties against dementia, which is becoming a major global public health issue. We conducted a systematic review of the literature to ...

People with multiple sclerosis (MS) seem to experience significant changes in cognition more than a year before significant physical decline is evident, a study found. While measures of processing ...

At the Type B end-of-Phase 2 MS meeting with the U.S. Food and Drug Administration, FDA aligned with Clene acknowledging the limitations of the Expanded Disability Status Scale and expressed openness ...